Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,851 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pembrolizumab Clear all

Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions: Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Glioblastoma
Interventions: MK - 3475, Suppressor of the PI3K/Akt pathways; Drug · Biological
Lead sponsor: Medical Research Council; Government
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Uveal Melanoma
Interventions: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab; Biological · Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions: Vepugratinib, Placebo, EV, Pembrolizumab; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more

Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Carboplatin, Pembrolizumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 552
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more

Conditions: Urothelial Carcinoma
Interventions: Zilovertamab vedotin, Pembrolizumab, MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
Interventions: M032, Pembrolizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions: Reirradiation, MK-3475; Radiation · Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 4
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab, CISPLATIN, Carboplatin, Docetaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions: Pembrolizumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
Interventions: Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET), Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Locally Advanced Solid Tumor
Interventions: TNG462, Pembrolizumab; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more

Conditions: Advanced/Metastatic NSCLC
Interventions: Immunotherapy - PD-1 Blocker; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioblastoma, Glioblastoma, WHO Grade IV
Interventions: Temozolomide (TMZ), Optune System, Pembrolizumab; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 55
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more

Conditions: Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions: AMG820 and pembrolizumab; Biological
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 4 more

Conditions: Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 254
States / cities: Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more

Conditions: Cancer, Prostate Cancer
Interventions: ADXS31-142, Pembrolizumab; Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Rockville, Maryland + 4 more

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacodynamic Study; Drug · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Duarte, California • South Pasadena, California • West Covina, California

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor; Procedure · Biological · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 182
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more

Conditions: Malignant Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more

Search by objective public record fields.

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Study of Pembrolizumab and M032 (NSC 733972)

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Impact of Circadian Rhythm on Immunotherapy

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)